Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi, Eisai Look Beyond Japan To Expanded Markets In Southeast Asia (Japan)

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo and Eisai are reaching beyond their Japan bases into other Asian markets to seek faster growth than they are seeing at home. Daiichi is looking to India as a good market for some of its flagship products, beginning in the spring, and is hiring a 100-person sales force, but Taiwan and other Asian markets also are in Daiichi plans. Eisai plans drug trials in China where it hopes to tap into a huge market, beginning with one for hepatitis B. Also in Eisai plans are member countries of the Association of Southeast Asian Nations where Eisai is looking for a 20 percent annual sales increase. (Click here for more - may require a subscription

You may also be interested in...



Japanese Pharma Majors Expanding Into India

NEW DELHI - Faced with margin pressures elsewhere, pharmaceutical multinationals have been eyeing the burgeoning Indian market ever since the country signed the Trade-Related Aspects of Intellectual Property Rights pact. Initially hesitant, Japanese pharma companies are now following in the footsteps of Western companies, using India as a hub for low-cost contract manufacturing and clinical trials

Industry Self-Regulation Group’s Knowledge Of Drug Types Questioned By US Homeopathic Firm

Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.

Novartis Takes Huntington's Path With SMA Therapy Branaplam

With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel